Key result
The MESSAGE-HF trial is an ongoing randomized controlled trial designed to evaluate the efficacy of an automated text messaging and telephone support strategy on NT-proBNP levels at 180 days in patients with recent heart failure hospitalization.
Why the study?
The study was designed to evaluate a telemonitoring strategy based on automated text messaging and telephone support after heart failure hospitalization.
Does a telemonitoring strategy based on automated text messaging and telephone support improve NT-proBNP levels in patients with recent heart failure admission and LVEF <40%?
RCT (n=700)
Open-label
1:1 ratio, blocks of four stratified by centre
Yes
Does a telemonitoring strategy based on automated text messaging and telephone support improve NT-proBNP levels in patients with recent heart failure admission and LVEF <40%?
The MESSAGE-HF trial is designed to evaluate whether a simple, tailored telemonitoring strategy using automated text messaging can improve NT-proBNP levels and self-care in patients recently hospitalized for heart failure.
Telemonitoring may support self-care in HFrEF post-discharge; leaves open effects on NT-proBNP and clinical outcomes.
AIMS: To evaluate a telemonitoring strategy based on automated text messaging and telephone support after heart failure (HF) hospitalization. METHODS AND RESULTS: The MESSAGE-HF study is a prospective multicentre, randomized, nationwide trial enrolling patients from 30 clinics in all regions of Brazil. HF patients with reduced left ventricular ejection fraction (<40%) and access to mobile phones are eligible after an acute decompensated HF hospitalization. Patients meeting eligibility criteria undergo an initial feasibility text messaging assessment and are randomized to usual care or telemonitoring intervention. All patients receive a HF booklet with basic information and recommendations about self-care. Patients in the intervention group receive four daily short text messages (educational and feedback) during the first 30 days of the protocol to optimize self-care; the feedback text messages from patients could trigger diuretic adjustments or a telephone call from the healthcare team. After 30 days, the frequency of text messages can be adjusted. Patients are followed up after 30, 90, and 180 days, with final status ascertained at 365 days by telephone. Our primary endpoint is the change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after 180 days. Secondary endpoints include changes in NT-proBNP after 30 days; health-related quality of life, HF self-care, and knowledge scales after 30 and 180 days; and a composite outcome of HF hospitalization and cardiovascular death, adjudicated by a blinded and independent committee. CONCLUSIONS: The MESSAGE-HF trial is evaluating an educational and self-care promotion strategy involving a simple, intensive, and tailored telemonitoring system. If proven effective, it could be applied to a broader population worldwide.
No takes yet. Share an insight, caveat, or question.
Rohde et al. (2021) conducted an RCT in Heart Failure with reduced Ejection Fraction (HFrEF) (n=700). Automated SMS text messaging and triggered nurse-led telephone interviews vs. Usual care plus standard HF booklet was evaluated on Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels assessed at baseline and 180 days after randomization. The MESSAGE-HF trial is an ongoing randomized controlled trial designed to evaluate the efficacy of an automated text messaging and telephone support strategy on NT-proBNP levels at 180 days in patients with recent heart failure hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: